[HTML][HTML] Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury
LA Ward, DSW Lee, A Sharma, A Wang, I Naouar… - JCI insight, 2020 - ncbi.nlm.nih.gov
Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of disease
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury.
LA Ward, DS Lee, A Sharma, A Wang, I Naouar, XI Ma… - JCI Insight, 2020 - europepmc.org
Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of disease
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
[HTML][HTML] Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury
LA Ward, DSW Lee, A Sharma, A Wang, I Naouar… - JCI …, 2020 - Am Soc Clin Investig
Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of disease
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury.
LA Ward, DS Lee, A Sharma, A Wang, I Naouar, XI Ma… - JCI insight, 2020 - sonar.ch
English Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of
disease progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
disease progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury.
LA Ward, DS Lee, A Sharma, A Wang, I Naouar, XI Ma… - JCI insight, 2020 - folia.unifr.ch
English Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of
disease progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
disease progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury
LA Ward, DS Lee, A Sharma, A Wang… - JCI …, 2020 - pubmed.ncbi.nlm.nih.gov
Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of disease
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury.
LA Ward, DS Lee, A Sharma, A Wang, I Naouar, XI Ma… - JCI Insight, 2020 - europepmc.org
Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of disease
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
[HTML][HTML] Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury
LA Ward, DSW Lee, A Sharma, A Wang, I Naouar… - JCI …, 2020 - Am Soc Clin Investig
Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of disease
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …
progression. Although the mechanism (s) that mediate pathogenesis in the subpial …